AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

(in millions, except per share data)	Quarter Ended December 31, 2023						Full-Year Ended December 31, 2023
	Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range				Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range
			Low		High				Low		High
Previously announced guidance excluding Q4 2023 acquired IPR&D and milestones expense	$	—	$	2.87	$	2.91	$	496	$	11.19	$	11.23
Q4 2023 acquired IPR&D and milestones expense	282		(0.15)		(0.15)		282		(0.15)		(0.15)
Guidance including Q4 2023 acquired IPR&D and milestones expense	$	282	$	2.72	$	2.76	$	778	$	11.04	$	11.08

    1